UK-5099, a mitochondrial pyruvate carrier inhibitor, recovers impaired neutrophil maturation caused by AK2 deficiency in human pluripotent stem cell models

Biochem Biophys Res Commun. 2023 Dec 20:687:149211. doi: 10.1016/j.bbrc.2023.149211. Epub 2023 Nov 3.

Abstract

Reticular dysgenesis (RD) is a rare genetic disease caused by gene mutations in the ATP:AMP phosphotransferase, adenylate kinase 2 (AK2). Patients with RD suffer from severe combined immunodeficiency with neutrophil maturation arrest. Although hematopoietic stem cell transplantation can be a curative option, it is invasive, and complications of agranulocytosis-induced infection worsen the prognosis. Here, we report that the use of UK-5099, an inhibitor of the mitochondrial pyruvate carrier (MPC), on hemo-angiogenic progenitor cells (HAPCs) derived from AK2-deficient induced pluripotent stem cells improved neutrophil maturation. Reactive oxygen species (ROS) levels in AK2-deficient HAPCs remained unchanged throughout all experiments, implying that UK-5099 improved the phenotype without affecting ROS levels. Overall, our results suggest that the MPC is a potential therapeutic target for the treatment of neutrophil maturation defects in RD.

Keywords: Adenylate kinase 2; Induced pluripotent stem cells; Neutrophils; Reticular dysgenesis; UK-5099.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenylate Kinase / metabolism
  • Humans
  • Monocarboxylic Acid Transporters*
  • Neutrophils / metabolism
  • Pluripotent Stem Cells* / metabolism
  • Reactive Oxygen Species / metabolism

Substances

  • 2-cyano-3-(1-phenylindol-3-yl)acrylate
  • Monocarboxylic Acid Transporters
  • Reactive Oxygen Species
  • Adenylate Kinase

Supplementary concepts

  • Reticular dysgenesis